BACKGROUND: This study generated new information about the outcomes of patients enrolled in antiretroviral treatment programmes, as well as the true outcomes of those lost to follow-up (LTF). METHODS: Anonymized data were collected for patients enrolled over a 12-month period from two programmes (public and private) in southeast Nigeria. Estimates of retention, LTF, mortality and transfers were computed. All LTF enrollees (defined as patients who had missed three scheduled visits) whose contact information met pre-defined criteria were traced. RESULTS: A total of 481 (public) and 553 (private) records were included. Median duration of follow-up was about 14 months. Cumulative retention and LTF proportions were 66·5 and 32·8% (public), and 82·6 and 11·0% (private) respectively. LTF rates at third, sixth, ninth and twelfth months were 7·5, 19·3, 25·4 and 29·6% respectively (public), and 4·1, 7·1, 9·0 and 10·0% (private). LTF was higher among males, patients with CD4(+) cell count ≤200 and public programme enrollees. For the public facility, 56·7% of 104 traceable patients were dead and 38·8% were alive; the figures were 34·2 and 60·5% of 46 patients respectively for the private. Most deaths had occurred by the third month. CONCLUSION: Not all patients enrolled for treatment were retained. Though some died, many were LTF, lived within the community, and could develop and transmit resistant viral stains. Most traced patients were dead by the third month and poor contact information limited the effectiveness of tracing. Antiretroviral treatment programmes need to improve documentation processes and develop and implement tracing strategies.
BACKGROUND: This study generated new information about the outcomes of patients enrolled in antiretroviral treatment programmes, as well as the true outcomes of those lost to follow-up (LTF). METHODS: Anonymized data were collected for patients enrolled over a 12-month period from two programmes (public and private) in southeast Nigeria. Estimates of retention, LTF, mortality and transfers were computed. All LTF enrollees (defined as patients who had missed three scheduled visits) whose contact information met pre-defined criteria were traced. RESULTS: A total of 481 (public) and 553 (private) records were included. Median duration of follow-up was about 14 months. Cumulative retention and LTF proportions were 66·5 and 32·8% (public), and 82·6 and 11·0% (private) respectively. LTF rates at third, sixth, ninth and twelfth months were 7·5, 19·3, 25·4 and 29·6% respectively (public), and 4·1, 7·1, 9·0 and 10·0% (private). LTF was higher among males, patients with CD4(+) cell count ≤200 and public programme enrollees. For the public facility, 56·7% of 104 traceable patients were dead and 38·8% were alive; the figures were 34·2 and 60·5% of 46 patients respectively for the private. Most deaths had occurred by the third month. CONCLUSION: Not all patients enrolled for treatment were retained. Though some died, many were LTF, lived within the community, and could develop and transmit resistant viral stains. Most traced patients were dead by the third month and poor contact information limited the effectiveness of tracing. Antiretroviral treatment programmes need to improve documentation processes and develop and implement tracing strategies.
Authors: Kara Wools-Kaloustian; Silvester Kimaiyo; Lameck Diero; Abraham Siika; John Sidle; Constantin T Yiannoutsos; Beverly Musick; Robert Einterz; Kenneth H Fife; William M Tierney Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Iruka N Okeke; Ramanan Laxminarayan; Zulfiqar A Bhutta; Adriano G Duse; Philip Jenkins; Thomas F O'Brien; Ariel Pablos-Mendez; Keith P Klugman Journal: Lancet Infect Dis Date: 2005-08 Impact factor: 25.071
Authors: Joseph Kwong-Leung Yu; Solomon Chih-Cheng Chen; Kuo-Yang Wang; Chao-Sung Chang; Simon D Makombe; Erik J Schouten; Anthony D Harries Journal: Bull World Health Organ Date: 2007-07 Impact factor: 9.408
Authors: Charles Kabugo; Sylver Bahendeka; Raymond Mwebaze; Samuel Malamba; David Katuntu; Robert Downing; Jonathan Mermin; Paul J Weidle Journal: J Acquir Immune Defic Syndr Date: 2005-04-15 Impact factor: 3.731
Authors: Antonio G Pacheco; Valeria Saraceni; Suely H Tuboi; Lawrence H Moulton; Richard E Chaisson; Solange C Cavalcante; Betina Durovni; José C Faulhaber; Jonathan E Golub; Bonnie King; Mauro Schechter; Lee H Harrison Journal: Am J Epidemiol Date: 2008-10-09 Impact factor: 4.897
Authors: Kathrin Zürcher; Anne Mooser; Nanina Anderegg; Olga Tymejczyk; Margaret J Couvillon; Denis Nash; Matthias Egger Journal: Trop Med Int Health Date: 2017-02-20 Impact factor: 2.622
Authors: Edith Apondi; John M Humphrey; Edwin Sang; Ann Mwangi; Alfred Keter; Beverly S Musick; Fred K Nalugoda; John Ssali; Elizabeth Bukusi; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Samuel Ayaya Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: Viviane D Lima; Anja Reuter; P Richard Harrigan; Lillian Lourenço; William Chau; Mark Hull; Lauren Mackenzie; Silvia Guillemi; Robert S Hogg; Rolando Barrios; Julio S G Montaner Journal: AIDS Date: 2015-09-10 Impact factor: 4.177
Authors: Muktar H Aliyu; Meridith Blevins; Karen M Megazzini; Deidra D Parrish; Carolyn M Audet; Naomi Chan; Chisom Odoh; Usman I Gebi; Mukhtar Y Muhammad; Bryan E Shepherd; C William Wester; Sten H Vermund Journal: Int Health Date: 2015-05-25 Impact factor: 2.473
Authors: Muktar H Aliyu; Meridith Blevins; Deidra D Parrish; Karen M Megazzini; Usman I Gebi; Mukhtar Y Muhammad; Mukhtar L Ahmed; Adiba Hassan; Bryan E Shepherd; Sten H Vermund; C William Wester Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Bo Langhoff Hønge; Sanne Jespersen; Pernille Bejer Nordentoft; Candida Medina; David da Silva; Zacarias José da Silva; Lars Ostergaard; Alex Lund Laursen; Christian Wejse Journal: BMJ Open Date: 2013-10-25 Impact factor: 2.692